04:34 AM EST, 12/03/2024 (MT Newswires) -- Vaxart ( VXRT ) said late Monday it has completed enrollment of the 400 participants in the sentinel cohort for its phase 2b trial comparing its oral COVID-19 vaccine candidate with an approved mRNA vaccine.

The cohort includes 200 participants receiving Vaxart's ( VXRT ) vaccine and 200 receiving the mRNA comparator.

The primary endpoint of the study is the relative efficacy of Vaxart's ( VXRT ) vaccine candidate compared with the mRNA vaccine for the prevention of symptomatic disease, the company said.